Y-mAbs Therapeutics (YMAB) - Operating Profitability

Official company branding of Y-mAbs Corp (YMAB)

Y-mAbs Therapeutics (YMAB) is developing radioimmunotherapy for rare pediatric tumors, expanding its presence across Asia and Europe. However, reliance on a single product and the complexities of global scaling create profitability risks. The operational efficiency trend clearly demonstrates these processes, and the current metric has settled at -31.20. Business resilience is based on patent protection and the regulatory approval of new indications.

YMAB - Y-mAbs Therapeutics Inc Operating Profit Rate over the range 07/04/2022 - 09/27/2025

Y-mAbs Therapeutics - analytical breakdowns and key metrics (YMAB)

- share price and consensus valuation forecast:
- market capitalization indicators:
Fundamental company analysis:YMAB, YmAbs
Finished products of Y-mAbs Corp

Y-mAbs Therapeutics (YMAB) is investing significant resources into developing antibodies for pediatric oncology in collaboration with Memorial Sloan Kettering. By analyzing the ratio of operating profit to revenue, an investor assesses the efficiency of cost management within the core business. This metric reveals the portion of profit remaining after operating expenses are paid, prior to accounting for financial obligations. The indicator's trend captures the company's ability to scale development without a disproportionate increase in costs, which determines the long-term fundamental stability of the business valuation.

Competitor analysis for Y-mAbs Therapeutics

Operating Profitability BeiGene Ltd|Halozyme Therapeutics - Operating Profit Margin|Operating Sales Margin RVMD (Revolution Medicines Corp)|Operating Profit Ratio AAPG|Operating Profitability CG Oncology Therapeutics CGON|Operating Profit Rate URGN|BCAX: Operating Sales Margin|PSNL: Operating Profitability|Erasca (ERAS) - Operating Profitability|DCTH - Profitability of Operations|AURA (Aura Biosciences Inc) - Operating Margin|Operating Return on Sales candeltx.com CADL|Operating Margin ARAY|SLS (SELLAS Life Sciences Group, Inc.) - Operating Profit Rate|Operating Profitability Actuate Therapeutics, Inc. ACTU|citiusonc.com - Operating Profitability|TuHURA Biosciences Inc. - Operating Margin|TARA - Operating Margin|FATE (Fate Therapeutics) - Operating Sales Margin|Operating Sales Margin Aadi Bioscience, Inc.|Operating Sales Margin TCRX|Operating Profitability CSBR|Operating Margin XBIT|Profitability of Operations CEL-SCI Corp.|Operating Profitability ostherapies.com OSTX|RADX: Return on Sales by Operating Profit|ARTV: Operating Sales Margin|ANL (Adlai Nortye) - Return on Sales by Operating Profit|Veru (VERU) - Operating Profitability|Operating Sales Margin Tempest Therapeutics Inc|Operating Profitability Xilio Therapeutics|Return on Sales by Operating Profit RENB (Renovaro Inc.)|Operating Profitability Mural Oncology PLC (MURA)|Operating Margin Kairos Pharma (KAPA)|Operating Profitability onkuretherapeutics.com OKUR|GDTC: Return on Sales by Operating Profit|CRIS: Operating Sales Margin|apollomicsinc.com (APLM) - Operating Sales Margin|THAR: Operating Margin|Operating Sales Margin Advanced Biomed Inc.|Operating Sales Margin GNPX|Return on Sales by Operating Profit CLDI (Calidi Biotherapeutics)|Operating Margin SBFM|Xenetic Biosciences, Inc. - Return on Sales by Operating Profit|Operating Profitability Salarius Pharmaceuticals SLRX|Operating Margin purple-biotech.com PPBT|AONC - Operating Profitability|BGNE: Operating Profitability|CKPT: Operating Margin|Elevation Oncology - Operating Profit Rate|ICAD (iCAD) - Operating Margin|IKNA: Operating Profit Rate|Operating Profitability Notable Labs (NTBL)|VIRX (Viracta Therapeutics, Inc.) - Operating Profit Rate|Operating Profitability MorphoSys Corporation MOR|NAYA: Return on Sales by Operating Profit|Ascentage Pharma Group International - Operating Margin